• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Iranian Journal of Neurology >Induction or aggravation of other immune-mediated disorders by disease-modifying therapy in treatment of multiple sclerosis
【24h】

Induction or aggravation of other immune-mediated disorders by disease-modifying therapy in treatment of multiple sclerosis

机译：通过疾病改良疗法诱导或加重其他免疫介导的疾病，治疗多发性硬化症

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Interferon beta (IFN-β) and glatiramer acetate (GA) are the primary therapeutic immunomodulatory agents that interfere with relapsing-remitting multiple sclerosis (RRMS), and the most commonly-used drugs as well. Induction or aggravation of other immune-mediated diseases has been reported following INF-β administration. We have reviewed the reported cases to notify the treating physicians about these rare adverse events. Although co-morbid autoimmune disorders have been reported in patients with MS, the pro-inflammatory role of disease-modifying drugs, especially INF-β, could affect and enhance this co-occurrence. Clinical or laboratory autoimmunity histories suggest the use of GA over INF-β as the treatment of choice.
机译：干扰素β（IFN-β）和醋酸格拉替雷（GA）是干扰复发缓解型多发性硬化症（RRMS）的主要治疗性免疫调节剂，也是最常用的药物。已经报道在施用INF-β后诱导或加剧其他免疫介导的疾病。我们已审查了所报告的病例，以将这些罕见的不良事件通知治疗医生。尽管在MS患者中已报告了并存的自身免疫性疾病，但疾病改变药物尤其是INF-β的促炎作用可能会影响并增强这种共存。临床或实验室自身免疫史建议使用GA替代INF-β作为治疗选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号